에 대한 최신 뉴스 Lantheus Holdings (NASDAQ:LNTH) 주식

Lantheus Holdings

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

News

ABBV

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 비폭력 마약 범죄자 석방를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다. AP 통신에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 트럼프의 취임식 하루 전이다.

딜 디스패치: 바이든이 틱톡 금지를 트럼프에게 넘기고, 또 다른 유명 소매업체 파산

Equities

Mid Cap

Movers

General

APGE

CRNX

JOBY

KYMR

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Analyst Color

Broad U.S. Equity ETFs

Small Cap

ETFs

EVGO

IGMS

MORF

OUST

PLSE

SOUN

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 2022년 1월 이후 최고 수준에 도달했다.

러셀 2000 지수, 연중 가장 강한 주를 기록하며 31개월 최고치를 기록

Lantheus Holdings Inc

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.00</td>
<td>$168.9K</td>
<td>10.7K</td>
<td>17.1K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$93.00</td>
<td>$49.9K</td>
<td>25</td>
<td>604</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$130.00</td>
<td>$42.9K</td>
<td>6.5K</td>
<td>520</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$53.5K</td>
<td>1.9K</td>
<td>112</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$30.00</td>
<td>$102.8K</td>
<td>436</td>
<td>56</td>
</tr>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$45.0K</td>
<td>124</td>
<td>47</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$650.00</td>
<td>$60.4K</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$65.7K</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$540.00</td>
<td>$27.6K</td>
<td>625</td>
<td>21</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding LXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 11262 contract(s) at a $1.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $168.9K, with a price of $15.0 per contract. There were 10734 open contracts at this strike prior to today, and today 17155 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option sweep that happens to be bearish, expiring in 24 day(s) on February 21, 2025. This event was a transfer of 316 contract(s) at a $93.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $49.9K, with a price of $158.0 per contract. There were 25 open contracts at this strike prior to today, and today 604 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 272 contract(s) at a $130.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $42.9K, with a price of $158.0 per contract. There were 6570 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 143 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $57.50 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $535.0 per contract. There were 1923 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
• Regarding AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we observe a call option trade with neutral sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 46 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $102.8K, with a price of $2235.0 per contract. There were 436 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a call option sweep that happens to be bullish, expiring in 143 day(s) on June 20, 2025. This event was a transfer of 47 contract(s) at a $100.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $45.0K, with a price of $968.0 per contract. There were 124 open contracts at this strike prior to today, and today 47 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a call option trade with bearish sentiment. It expires in 234 day(s) on September 19, 2025. Parties traded 30 contract(s) at a $650.00 strike. The total cost received by the writing party (or parties) was $60.4K, with a price of $2016.0 per contract. There were 70 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with bullish sentiment. It expires in 52 day(s) on March 21, 2025. Parties traded 25 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $65.7K, with a price of $2630.0 per contract. There were 6 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 79 day(s) on April 17, 2025. This event was a transfer of 10 contract(s) at a $540.00 strike. The total cost received by the writing party (or parties) was $27.6K, with a price of $2760.0 per contract. There were 625 open contracts at this strike prior to today, and today 21 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

LXRX

REGN

9 Health Care Stocks With Whale Alerts In Today's Session

On Tuesday,&nbsp;Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of&nbsp;$250 million&nbsp;and up to an additional&nbsp;$752.5 million&nbsp;in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43261004/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-" rel="noreferrer noopener">potential milestone payments</a>.
Evergreen is a clinical-stage radiopharmaceutical company that offers Contract Development and Manufacturing (CDMO) services, drug discovery, and the commercialization of proprietary products.
This transaction will solidify Lantheus&#8217; capabilities as a fully integrated radiopharmaceutical company.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39717130/new-reimbursement-rules-for-diagnostic-radiopharmaceuticals-is-undoubtedly-positive" rel="noreferrer noopener">New Reimbursement Rules For Diagnostic Radiopharmaceuticals Is &#8216;Undoubtedly&#8217; Positive for Lantheus: Analyst</a>
The acquisition also expands Lantheus&#8217; oncology diagnostic pipeline by adding both OCTEVY, a registrational-stage PET diagnostic agent for certain neuroendocrine tumors (NETs) that could complement Lantheus&#8217; therapeutic candidate PNT2003, as well as several clinical and pre-clinical novel theranostic pairs.
The transaction is expected to close in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43261004/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-" rel="noreferrer noopener">second half of 2025</a>.
The company also reaffirmed its fiscal year 2024 revenue guidance of $1.51 billion—$1.52 billion and adjusted EPS of $6.65-$6.70, compared to consensus of $1.52 billion and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">$6.74, respectively</a>.
Last week, Lantheus agreed to acquire Life Molecular Imaging in an all-cash transaction consisting of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments.
Life Molecular, a Life Healthcare Group Holdings Ltd&#8217;s subsidiary, offers Positron Emission Tomography (PET) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42937211/lantheus-to-acquire-life-molecular-imaging-for-an-upfront-payment-of-350-million-to-accelerate-inn" rel="noreferrer noopener">radiopharmaceutical diagnostics</a>.
The acquisition is expected to immediately enhance Lantheus&#8217; near and long-term growth profile and establish a commercial Alzheimer&#8217;s disease (AD) franchise with the addition of Neuraceq&nbsp;(florbetaben F18 injection), a F-18 radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline.
The transaction is expected to be accretive to Lantheus&#8217; Adjusted Earnings Per Share within 12 months of close.
Price Action: At last check on Tuesday, LNTH stock was down 5.56% to $92.85.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43260646/microsoft-eyes-tiktok-us-deal-as-trump-confirms-acquisition-talks-are-underway" target="_blank" rel="noreferrer noopener">Microsoft Eyes TikTok US Deal, Trump Says Acquisition Talks Are Underway</a></li>
</ul>

Health Care

Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio

WIIM

Lantheus shares are trading lower after the company issued FY24 adjusted EPS guidance below estimates. Additionally, the company announced it agreed to acquire Evergreen Theragnostics.

Earnings

Guidance

Lantheus Reaffirms FY 2024 Revenue Of $1.51B-$1.52B, And Adjusted EPS Of $6.65-$6.70 Compared To Consensus Of $1.52B And $6.74, Respectively

<ul>
<li>Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities</li>
<li>Adds OCTEVY, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent, PNT2003</li>
<li>Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs</li>
</ul>

Lantheus Agreed To Acquire Evergreen Theragnostics In An All-cash Transaction Consisting Of An Upfront Payment Of $250M And Up To An Additional $752.5M In Potential Milestone Payments

President Joe Biden prioritized <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">freeing non-violent drug offenders</a> during his final few days in the White House, but TikTok? That's President-elect Donald Trump's problem now. 
According to the <a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">Associated Press</a>, Biden has no intention of enforcing the ban, which takes effect on his last full day in office, Jan. 19, and one day <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">before Trump&#8217;s inauguration</a>.
With a deadline looming, the app's fate lands in the hands of the so-called People's Bid for TikTok—backed by none other than Kevin O'Leary of &#8220;Shark Tank&#8221; and billionaire Frank McCourt. Apparently, TikTok's U.S. assets are still up for grabs, but no word yet on the price tag or whether a deal can realistically get done <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">in a few days</a>.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Joann Inc. is stitching together a bankruptcy plan for the second time within 12 months. The Ohio-based fabric and crafts retailer is seeking a buyer for its portfolio of some 800 stores. 
Gordon Brothers Retail Partners emerged as the &#8220;stalking horse&#8221; bidder, but Joann remains hopeful for better offers—perhaps from someone who knows how to thread the needle.
Previously, the 82-year-old retailer was under the stewardship of private equity firm Leonard Green &amp; Partners, which acquired it via a $1.6 billion leveraged buyout in 2011. The firm buried the company under a pile of debt (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">reportedly</a> $921 million in long-term debt as of Oct. 31, 2020) and <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">sent it public in 2021</a>. 
Joann went private again in <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">March</a> 2024 while under Chapter 11 bankruptcy protection. The company managed to reduce its $1 billion total debt by about $500 million at the time.
Despite efforts to save itself last year, Joann is joining the growing quilt of recent retail casualties: Party City, Big Lots, LL Flooring, The Body Shop and The Container Store <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">to name a few</a>.
Kirkland &amp; Ellis is handling legal matters, while Centerview Partners LLC offers financial advice. Alvarez &amp; Marsal North America, LLC is overseeing the restructuring process.
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Investment firm KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) hired Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to run an auction for its minority stake in Philippine fintech company Maya, Reuters reported. </li>
<li>New York-headquartered KKR owns more than 20% of Maya and the potential sale, if it goes through, could value Maya at more than $2 billion, one of the sources said.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is looking to <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">jettison its electronics business</a>. The Wilmington, Delaware-based company expects the transaction to be completed by Nov. 1. DuPont also decided to retain its water business after evaluating strategic alternatives.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is shopping its Performance Chemicals Industrial Specialties segment, which includes divesting parts of its North Charleston, South Carolina site. The company hopes to improve earnings cash flow and conclude the review process by year-end. Whether a transaction comes about <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">remains to be seen</a>. </li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) is up for sale. It&#8217;s also considering a merger or recapitalization as part of a larger strategic review. The Longmont, Colorado-based company has already sold its Australia subsidiary. &#8220;We continue to support all initiatives that optimize shareholder value and will consider the full range of potential strategic alternatives to ensure S&amp;W Seed is best positioned for future success,&#8221; chairman Alan Willits said.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">Starship Explodes During Flight Test, Elon Musk Says: &#8216;Success Is Uncertain, But Entertainment Is Guaranteed!&#8217;</a>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Lourenco Goncalves raised eyebrows during a Monday press conference. According to <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">Bloomberg</a>, the CEO of Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) called Japan, a U.S. ally, &#8220;evil&#8221; and accused it of teaching China harmful practices like dumping and overproduction. His comments came as Cleveland-Cliffs eyes a new bid for U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), following Biden&#8217;s decision to block Nippon Steel&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$14 billion acquisition attempt</a>. While positioning his company as a potential buyer, Goncalves&#8217; rhetoric escalated tensions within the steel industry. Nippon is now looking to Trump to <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">help close the deal</a>. </li>
<li>T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) will buy Vistar Media for $600 million. The telecom company expects the deal to strengthen its advertising business, Reuters reported. </li>
</ul>
Deals in the biotech and pharmaceutical sectors piled up this week. Here&#8217;s a sample of Benzinga&#8217;s coverage:
<ul>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already own <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">for $7.22 per share</a>. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">agreed to acquire</a> IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. The deal may require an additional $150 million from GSK after certain regulatory approval milestones. </li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) scooped up Scorpion Therapeutics&#8217; early-stage <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">cancer program for $2.5 billion</a>. </li>
<li>Like Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is seeking to bolster its neuropsychiatric portfolio<a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal"> with a $15 billion deal</a></li>
<li>Crown Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) offered to acquire all outstanding common shares of Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at $3.10 per share.</li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) agreed to a deal with Decoy Therapeutics, a preclinical biotech focused on peptide conjugate therapeutics. The merged entity will target unmet needs in respiratory diseases and GI oncology.</li>
<li>Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) strengthens its radiopharmaceutical position with<a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging"> $350 million acquisition of Life Molecular Imaging</a>.</li>
</ul>
For last week&#8217;s edition of Deal Dispatch, <a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">Eccentric Billionaire, Legendary Filmmaker Howard Hughes&#8217; Former Miami Estate On Market For $55.5 Million</a></li>
</ul>
Image created with a photo from Shutterstock.

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Lantheus Holdings, revealing an average target of $121.75, a high estimate of $143.00, and a low estimate of $112.00. Observing a downward trend, the current average is 1.81% lower than the prior average price target of $124.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1736881258_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Lantheus Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$143.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$112.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lantheus Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Lantheus Holdings compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Lantheus Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Lantheus Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LNTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lantheus Holdings analyst ratings.</a>
<h2>About Lantheus Holdings</h2>
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
<h3>Lantheus Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Lantheus Holdings showcased positive performance, achieving a revenue growth rate of 18.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Lantheus Holdings's net margin is impressive, surpassing industry averages. With a net margin of 34.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Lantheus Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lantheus Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of 6.57%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 4 Analyst Ratings Have To Say About Lantheus Holdings

JMP Securities analyst David Turkaly reiterates Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Market Outperform and maintains $112 price target.

Price Target

Reiteration

JMP Securities Reiterates Market Outperform on Lantheus Holdings, Maintains $112 Price Target

Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) shares are trading lower by 4.4% to $91.64 during Monday&#8217;s session after the company announced a <a href="https://www.benzinga.com/pressreleases/25/01/g42937211/lantheus-to-acquire-life-molecular-imaging-for-an-upfront-payment-of-350-million-to-accelerate-inn">$350 million acquisition</a>.
What To Know: Lantheus Holdings announced the acquisition of Life Molecular Imaging Ltd. in a deal valued at up to $750 million, including $350 million upfront and up to $400 million in milestone payments. 
The company says the acquisition expands Lantheus' presence in Alzheimer's disease (AD) diagnostics with Neuraceq, an F-18 radioactive diagnostic agent for PET imaging of β-amyloid plaque in cognitively impaired patients.
Lantheus says Life Molecular brings advanced R&amp;D capabilities, international infrastructure and a strong commercial presence, enabling Lantheus to enhance its diagnostic and therapeutic offerings. 
CEO Brian Markison highlighted the acquisition&#8217;s alignment with Lantheus' growth strategy, emphasizing its potential to improve patient outcomes and deliver shareholder value.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42944934/wall-street-slashes-interest-rate-cut-bets-after-jobs-data-are-hikes-back-on-the-table">Wall Street Slashes Interest Rate Cut Bets After Jobs Data: Are Hikes Back On The Table?</a>
<h2 class="wp-block-heading">How To Buy LNTH Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Lantheus Holdings&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LNTH has a 52-week high of $126.89 and a 52-week low of $50.20.

Why Lantheus Holdings (LNTH) Stock Is Down 4%

Lantheus Holdings shares are trading lower after the company announced a $350 million acquisition.

<ul>
<li>Enhances Lantheus' growth profile with Neuraceq&#xAE;, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease</li>
<li>Advances Lantheus' radiopharmaceutical leadership with addition of Alzheimer's radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&amp;D capabilities</li>
<li>Transaction expected to be accretive to adjusted EPS within the first 12 months</li>
<li>Company to host conference call on January 13, 2025, at 8:30 AM EST</li>
</ul>

Lantheus Strengthens Radiopharmaceutical Leadership With $350M Acquisition Of Life Molecular Imaging

<ul>
<li>Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 million</li>
<li>Placement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024</li>
<li>Lantheus shareholding in Radiopharm increases to 12.16% following the placement</li>
<li>The funds raised will be applied to the development of Radiopharm's clinical pipeline</li>
</ul>
SYDNEY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has executed a subscription agreement for a private placement of ordinary shares to Lantheus Holdings Inc. ( "Lantheus"), raising US$5.0 million (A$8.0 million).
The placement of 133 million shares was completed at an issue price of A$0.060 per share, representing a 150% premium to the last traded price of RAD shares (A$0.024). Settlement is expected to occur within 7 days.
The placement replaces 6-month options that the Company issued in August 2024 (see ASX announcement 20 June 2024).

Offerings

Contracts

RADX

Radiopharm Theranostics Executed A Subscription Agreement For A Private Placement Of Ordinary Shares To Lantheus Holdings Inc., Raising $5M

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) has outperformed the market over the past 5 years by 23.29% on an annualized basis producing an average annual return of 36.08%. Currently, Lantheus Holdings has a market capitalization of $6.19 billion. 
Buying $1000 In LNTH: If an investor had bought $1000 of LNTH stock 5 years ago, it would be worth $4,630.01 today based on a price of $89.16 for LNTH at the time of writing.
<h3>Lantheus Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735920908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

A substantial insider activity was disclosed on December 24, as MARKISON, CEO at Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), reported the exercise of a large sell of company stock options.
What Happened: MARKISON, CEO at Lantheus Holdings, made a strategic move by exercising stock options for 32,768 shares of LNTH as detailed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001521036/000106299324021182//Archives/edgar/data/1521036/000106299324021182/0001062993-24-021182-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $2,731,057.
Lantheus Holdings shares are trading, exhibiting up of 1.64% and priced at $92.5 during Tuesday's morning. This values MARKISON's 32,768 shares at $2,731,057.
<h3>About Lantheus Holdings</h3>
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
<h3>Lantheus Holdings's Economic Impact: An Analysis</h3>
Positive Revenue Trend: Examining Lantheus Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.37% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 63.93%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Lantheus Holdings's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.89.
</li>
</ul>
Debt Management: Lantheus Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.52, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 15.12 is lower than the industry average, implying a discounted valuation for Lantheus Holdings's stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 4.32 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lantheus Holdings's EV/EBITDA ratio at 9.32 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001521036">Check Out The Full List Of Lantheus Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Options Exercise: BRIAN MARKISON At Lantheus Holdings Realizes $2.73M

In the current session, the stock is trading at $93.06, after a 0.44% spike. Over the past month, Lantheus Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock increased by 7.65%, and in the past year, by 56.81%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_0.png" alt="Past Year Chart" />

<h3>Lantheus Holdings P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Lantheus Holdings has a lower P/E than the aggregate P/E of 48.6 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Lantheus Holdings

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Paul Choi initiated coverage on Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy rating and announced a price target of $143. Lantheus shares closed at $92.66 on Tuesday. See how other analysts view this stock.</li>
<li>DA Davidson analyst Lucky Schreiner initiated coverage on Box, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) with a Buy rating and announced a price target of $45. Box shares closed at $32.07 on Tuesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Brookline Capital analyst Kumaraguru Raja initiated coverage on Quince Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy rating and announced a price target of $9. Quince Therapeutics shares closed at $1.84 on Tuesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Tazeen Ahmad initiated coverage on KalVista Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Buy rating and announced a price target of $22. KalVista Pharma shares closed at $8.65 on Tuesday. See how other analysts view this stock.</li>
<li>Raymond James analyst Andrew Marok initiated coverage on DoubleVerify Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with an Outperform rating and announced a price target of $25. Fluor shares closed at $19.95 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BOX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="507" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-1024x507.png" alt="" class="wp-image-697929" style="width:604px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-1024x507.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18100141/image-159.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42551008/top-3-health-care-stocks-that-may-explode-in-q4">Read This Next: </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42551008/top-3-health-care-stocks-that-may-explode-in-q4">Top 3 Health Care Stocks That May Explode In Q4</a></li>
</ul>

Initiation

KALV

QNCX

This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Goldman Sachs analyst Paul Choi initiates coverage on Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy rating and announces Price Target of $143.

Goldman Sachs Initiates Coverage On Lantheus Holdings with Buy Rating, Announces Price Target of $143

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) has outperformed the market over the past 5 years by 20.97% on an annualized basis producing an average annual return of 34.66%. Currently, Lantheus Holdings has a market capitalization of $6.35 billion. 
Buying $1000 In LNTH: If an investor had bought $1000 of LNTH stock 5 years ago, it would be worth $4,461.65 today based on a price of $91.42 for LNTH at the time of writing.
<h3>Lantheus Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734102018_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Lantheus Holdings Stock In The Last 5 Years

Lantheus Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NYSE">LNTH</a>) short percent of float has risen 6.28% since its last report. The company recently reported that it has 4.45 million shares sold short, which is 8.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lantheus Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733841017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lantheus Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lantheus Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lantheus Holdings's peer group average for short interest as a percentage of float is 6.33%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Lantheus Holdings?

Lantheus Holdings shares are trading higher after the company announced its board authorized a $250 million share repurchase program.

Lantheus to acquire Evergreen Theragnostics

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of ...

Lantheus to acquire Evergreen Theragnostics for $250M upfront

Lantheus ( ($LNTH) ) has shared an update. On January 27, 2025, Lantheus Medical Imaging, a subsidiary of Lantheus Holdings, announced an agreement...

Lantheus to Acquire Evergreen Theragnostics for $250 Million

In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Lantheus (LNTH – Research Report), with a price target of $13...

Lantheus Holdings' Strategic Advancements and Acquisitions Reinforce Buy Rating

In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Lantheus (LNTH – Research Report), with a price target of ...

Strategic Expansions and Acquisitions Position Lantheus for Growth in Oncology and Radiopharma Sectors

TD Cowen analyst Tara Bancroft maintained a Buy rating on Lantheus (LNTH – Research Report) today and set a price target of $110.00. The company's ...

TD Cowen Sticks to Its Buy Rating for Lantheus (LNTH)

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Lantheus (LNTH – Research Report). The company's shar...

Truist Financial Keeps Their Buy Rating on Lantheus (LNTH)

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday. Roanna Ruiz's rating is base...

Lantheus's Strategic Acquisition of Evergreen Theragnostics Strengthens Radiopharmaceutical Leadership and Growth Prospects

An update from Lantheus ( ($LNTH) ) is now available. Lantheus Holdings, Inc. announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., to its...

Lantheus Appoints Dr. Morrow to Board of Directors

Lantheus (LNTH) announced the appointment of Phuong Khanh Morrow, M.D. to Lantheus' Board of Directors, effective February 1, 2025. As an independe...

Lantheus appoints Morrow as new board member

Press Releases

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

Lantheus Reports Third Quarter 2024 Financial Results

Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025

Lantheus to Present at the Jefferies London Healthcare Conference

Lantheus Announces Share Repurchase Program

Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Management

Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

Align Tech

Avanos Medical

Bioventus

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Embecta

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

Haemonetics

ICU Medical

OrthoPediatrics

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems

Neogen

InspireMD

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

Rockwell Medical

RxSight

Sanara MedTech

Solventum

Staar Surgical

TELA Bio

UFP Techs

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

VolitionRX

Dentsply Sirona

Xtant Medical Holdings, Inc. Common Stock

Xtant Medical Hldgs

JMP Securities

Goldman Sachs

Truist Securities

Redburn Atlantic

B. Riley Securities

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">비폭력 마약 범죄자 석방</a>를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다.
<a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">AP 통신</a>에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">트럼프의 취임식 하루 전</a>이다.
마감일이 다가오면서, 이 앱의 운명은 소위 &#8216;틱톡을 위한 국민 입찰&#8217;에 달려 있다. 이는 &#8220;샤크 탱크&#8221;의 케빈 오리어리(Kevin O&#8217;Leary)와 억만장자 프랭크 매코트(Frank McCourt)의 지원을 받는다. 분명히 틱톡의 미국 자산은 여전히 ​​손에 넣을 수 있지만 가격표나 거래가 <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">며칠 안에</a> 현실적으로 완료될 수 있는지 여부에 대해서는 아직 언급이 없습니다.
<h2 class="wp-block-heading">파산 블록</h2>
조앤(Joann Inc.)은 12개월 이내에 두 번째 파산 계획을 수립하고 있다. 오하이오 기반의 이 패브릭 및 공예 소매업체는 약 800개 매점의 포트폴리오 구매자를 찾고 있다.
고든 브라더스 리테일 파트너스(Gordon Brothers Retail Partners)가 "스톡킹 호스(stalking horse)" 입찰자로 나타났지만, 조앤은 여전히 더 나은 제안을 기대하고 있다. 아마도 바늘귀를 통과시키는 법을 아는 사람에게서 말이다.
이전에 82세의 소매업체는 사모펀드 레너드 그린 앤 파트너스(Leonard Green &amp; Partners)의 관리 하에 있었으며, 2011년 16억 달러의 레버리지 인수로 인수되었다. 이 회사는 부채에 묶여 있었고 (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">보도에 따르면</a> 2020년 10월 31일 기준 장기 부채가 9억 2,100만 달러였음) <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">2021년에 상장</a>되었다.
조앤은 <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">2024년 3월</a>에 다시 비공개로 전환되었으며, 당시 10억 달러의 총 부채를 약 5억 달러 줄이는 데 성공했다.
지난해 자구 노력이 무색해진 조앤은 최근 소매업체들의 증가하는 피해 사례에 합류하고 있다: <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">몇 가지를 예로 들면</a> 파티 시티(Party City), 빅랏츠(Big Lots), LL 플로링(LL Flooring), 더바디샵(The Body Shop) 및 더 컨테이너 스토어(The Container Store) 등이 있다.
컬크랜드 앤 앨리스(Kirkland &amp; Ellis)가 법률 문제를 처리하고 있으며, 센터뷰 파트너스(Centerview Partners LLC)가 재무 자문을 제공한다. 알바레즈 앤 마살 북미(Alvarez &amp; Marsal North America, LLC)가 구조조정 과정을 감독하고 있다.
<h2 class="wp-block-heading">신규 블록</h2>
<ul>
<li>투자 회사 KKR &amp; 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)가 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)를 고용하여 필리핀 핀테크 회사 마야(Maya)의 지분 매각 경매를 운영하도록 했다고 로이터가 보도했다.</li>
<li>뉴욕에 본사를 둔 KKR은 마야의 20% 이상의 지분을 보유하고 있으며, 매각이 진행된다면 마야의 가치는 20억 달러를 초과할 수 있다고 한 소식통이 전했다.</li>
<li>듀폰(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>)은 <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">전자 사업 분리</a>를 추진하고 있다. 델라웨어 주 윌밍턴에 본사를 둔 이 회사는 거래가 11월 1일까지 완료될 것으로 예상하고 있다. 듀폰은 전략적 대안을 평가한 후 수자원 사업을 유지하기로 결정했다.</li>
<li>인제비티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>)는 성과 화학 산업 전문 분야를 매각하고 있으며, 사우스 캐롤라이나주 노스 찰스턴 부지의 일부를 매각할 계획다. 이 회사는 이익 현금 흐름을 개선하고 검토 과정을 연말까지 마무리할 것으로 기대하고 있다. 거래 여부는 <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">아직 미정</a>이다.</li>
<li>S&amp;W 시드 컴퍼니(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>)는 매물에 나와 있다. 이는 합병 또는 재자본화도 고려 중이며, 이는 더 큰 전략적 검토의 일환이다. 콜로라도주 롱몬트에 본사를 둔 이 회사는 호주 자회사를 이미 매각했다. 앨런 윌리츠(Alan Willits) 회장은 "우리는 주주 가치를 최적화하는 모든 이니셔티브를 지원하고 있으며, S&amp;W 시드가 향후 성공을 위해 최적의 위치에 있도록 보장하기 위해 잠재적 전략적 대안의 전체 범위를 고려할 것이다"라고 밝혔다.</li>
</ul>
참고: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">스타 비행 시험 중 폭발, 일론 머스크: ‘성공은 불확실하지만 오락은 보장된다!'</a>
<h2 class="wp-block-heading">블록 업데이트</h2>
<ul>
<li>로렌코 곤칼베스(Lourenco Goncalves)는 월요일 기자 회견에서 주목을 받았다. <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">블룸버그</a>에 따르면, 클리브랜드 클리프스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>)의 CEO는 일본을 "악당"이라고 부르며, 중국에 해로운 관행인 덤핑과 과잉 생산을 가르쳤다고 비난했다. 그의 발언은 클리브랜드 클리프스가 U.S. 스틸(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>)에 대한 새로운 입찰을 노리고 있는 가운데 나왔으며, 바이든이 일본제철(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>)의 <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$140억 인수 시도</a>를 차단하기로 결정한 후이다. 자신의 회사를 잠재적 구매자로 포지셔닝하면서 곤칼베스의 수사는 철강 산업의 긴장을 고조시켰다. 일본제철은 이제 트럼프에게 <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">거래 성사를 도와달라고 요청</a>하고 있다.</li>
<li>T-모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)은 비스타 미디어(Vistar Media)를 6억 달러에 인수할 것이다. 이 통신 회사는 이 거래가 광고 사업을 강화할 것으로 기대하고 있다고 로이터가 보도했다.</li>
</ul>
지난주 생명공학 및 제약 부문 거래가 잇따랐다. 다음은 벤징가의 보도 샘플이다:
<ul>
<li>바이오젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)은 세이지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)의 모든 미상환 주식을 <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">주당 7.22달러에 인수하겠다는</a> 비공식 제안을 제출했다. 골드만삭스 애널리스트인 살빈 리히터(Salveen Richter)는 이 제안이 출산 후 우울증(PPD) 치료제인 주르주배(Zurzuvae) 런칭의 재무적 성공을 고려할 때 전략적으로 타당하다고 믿고 있다.</li>
<li>GSK plc(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)는 <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">IDRx, Inc., 위장관 간질성 종양(GIST)을 위한 정밀 치료제에 초점을 맞춘 생명공학 회사</a>를 10억 달러에 인수하기로 합의했다. 이 거래는 특정 규제 승인 이정표 후 GSK가 추가로 1억 5천만 달러를 지불해야 할 수도 있다.</li>
<li>일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 스콜피온 테라퓨틱스(Scorpion Therapeutics)의 초기 단계 <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">암 치료 프로그램을 25억 달러에 인수</a>했다.</li>
<li>브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)와 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 마찬가지로, 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)는 <a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal">150억 달러 거래로</a> 신경정신적 포트폴리오를 강화하려고 합니다.</li>
<li>크라운 래버러토리즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>)는 레반스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>)의 모든 미상환 보통주를 주당 3.10달러에 인수하겠다고 제안했다.</li>
<li>셀러리어스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)는 디코이 테라퓨틱스(Decoy Therapeutics)와의 거래를 체결했다. 이 회사는 펩타이드 접합 치료제에 초점을 맞춘 초기 단계 생명공학 회사이다. 통합된 개체는 호흡기 질환과 위장관 종양학의 미충족 요구 사항을 목표로 할 것이다.</li>
<li>란테우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)는 <a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging">3억 5천만 달러에 라이프 몰레큘러 이미징을 인수하여</a> 방사선 치료제 분야에서의 입지를 강화했다.</li>
<li> </li>
</ul>
지난주 딜 디스패치의 에디션은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-td-%EC%9D%80%ED%96%89%EC%9D%B4-%EC%B0%B0%EC%8A%A4-%EC%8A%88%EC%99%91-%EC%A7%80%EB%B6%84%EC%9D%84-%ED%8C%90%EB%A7%A4%ED%95%A0%EA%B9%8C-%EC%95%84/" target="_blank" rel="noopener">여기를 클릭하세요</a><a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">.</a>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">엑센트릭한 억만장자, 전설적인 영화 제작자 하워드 휴즈의 전 마이애미 저택이 5천 550만 달러에 매물로 나왔습니다.</a></li>
</ul>
이미지는 Shutterstock의 사진을 사용하여 생성되었습니다.


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>퀀텀스케이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 <a href="https://www.benzinga.com//node/39727990" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">전고체 배터리 산업화</a> 계약을 체결했다고 발표한 후 64.34% 급등했다.</li>
<li>랜티우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)의 주가는 전문 <a href="https://www.benzinga.com//node/39717130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">진단 방사성 의약품</a>에 대한 지불 개선을 위한 CMS 제안 이후 55.93% 급등했다.</li>
<li>선런(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)의 주가는 37.59% 상승했다. 최근 CPI 데이터에 따라 더 넓은 산업 분야의 기업 주가가 상승했기 때문이다.</li>
<li>키메라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>)의 주가는 화농한선염과 아토피성 피부염에 대한 임상 2상을 확대해 <a href="https://www.benzinga.com//node/39675035" target="_blank" rel="noreferrer noopener">안전성 및 유효성</a>에 대한 중간 검토를 거쳐 중추적 연구로 보다 신속하게 진행하겠다는 의사를 밝힌 뒤 37.38% 상승했다.</li>
<li>아포지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>)의 주식은 35.68% 급등했다.</li>
<li>조비 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>)은 회사가 <a href="https://www.benzinga.com//node/39733461" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">물을 유일한 부산물</a>로 사용하여 523마일을 수소 전기 항공 택시 시연차로 성공적으로 비행했다고 발표한 후 주가는 29.10% 상승했다.</li>
<li>크리네틱스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>)은 JP모건이 <a href="https://www.benzinga.com/quote/crnx/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 47달러에서 54달러로</a> 상향 조정한 후 주가는 21.18% 상승했다.</li>
<li>다인 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>)은 JP모건이 주식에 대해 비중확대 등급을 유지하고 <a href="https://www.benzinga.com/quote/DYN/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 39달러에서 43달러로</a> 높인 후 주가는 19.75% 상승했다.</li>
<li>서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식은 지난주 17.24% 급등했다.</li>
<li>플러그 파워(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>)의 주가는 <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39728268/inflation-slows-more-expected-to-3-in-june-heightens-expectations-for-rate-cuts-t" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">최근 소비자물가지수(CPI) 발표</a> 이후 전기차 관련주가 상승하면서 16.51% 상승했다. 미국 에너지부는 또한 폐쇄되었거나 위험에 처한 11개의 자동차 시설을 전기 자동차와 공급망 제조를 위해 전환하는 데 17억 달러를 투자한다고 발표했다.</li>
<li>샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)의 주식은 15.56% 상승했다. 6월 중국의 수출이 증가한 것을 계기로 중국 관련 주식이 상승했다.</li>
</ol>
기타 읽어볼 만한 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%eb%b0%94%ec%9d%b4%eb%91%90%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-11%ea%b0%9c%ec%9d%98-%eb%8c%80/" target="_blank" rel="noopener">리비안과 바이두는 지난주 최고 성과를 보인 11개의 대형주 주식 중 일부 (7월 7일-7월 13일)</a></li>
<li><a href="https://kr.benzinga.com/news/%eb%84%b7%ed%94%8c%eb%a6%ad%ec%8a%a4%ec%99%80-%eb%8d%b8%ed%83%80-%ed%95%ad%ea%b3%b5%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10/" target="_blank" rel="noopener">넷플릭스와 델타 항공은 지난주 최악의 성과를 보인 10대 대형주 중 일부 (7월 7일-7월 13일)</a></li>
</ul>
Photo Courtesy of QuantumScape
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 <a href="https://www.benzinga.com/topic/small-caps" target="_blank" rel="noopener" data-google-interstitial="false">2022년 1월 이후</a> 최고 수준에 도달했다.
이러한 랠리는 주로 목요일 세션에 의해 주도되었으며, 러셀 2000 지수는 일일 3.6%라는 놀라운 상승률을 기록했다. 이번 급등은 예상보다 낮은 6월 인플레이션 데이터에 따른 것이며, 이로 인해 잠재적인 금리 인하 가능성에 대한 기대가 강화되었다.
그러나 LPL 파이낸셜의 최고 글로벌 전략가인 퀸시 크로스비(Quincy Krosby)는 러셀 2000의 금리 인하 메시지가 &#8220;노동 시장에 대한 연방준비제도(연준)의 우려로 인해 흐려질 수 있다&#8221;고 시사하면서 주의를 조언했다.
크로스비는 노동시장 약화가 경제적으로 민감한 러셀 2000 지수에 여전히 타격을 줄 것이며, 금리 인하가 반드시 더 광범위한 경기 둔화로부터 지수를 보호할 수는 없을 것이라고 생각한다.
<h2 class="wp-block-heading">이번 주의 차트: 8개월 만에 최대 성과를 올린 소형주 지수</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-434094" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-768x366.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1536x732.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21.png 1920w" alt="" width="1024" height="488" /></figure>
출처: <a href="URL http://www.benzinga.com/pro/register/?utm_source=BZprocontent071224&amp;t=be2bearmibe3na1">Benzinga Pro</a>
러셀 2000의 인상적인 성과는 투자자들이 거대 기술 기업들에서 벗어나 더 넓은 시장으로 직접 유입됨에 따라 금리에 민감한 중소형주가 이익을 얻는 등 시장 초점의 상당한 변화를 강조한다고 크로스비가 강조했다.
이 분석가는 러셀 2000이 잠재적인 금리 완화와 광범위한 경제 상황에 대한 중요한 지표 역할을 한다고 지적했다. 일반적으로 중소형주 유니버스는 매력적인 밸류에이션에도 불구하고 심각한 경기 둔화 조짐이 보이면 매도할 것이다.
"역사적으로 러셀 2000은 첫 번째 금리 인하 이후 3개월 동안 시장보다 뒤쳐졌다. 연준이 일반적으로 경제, 특히 노동 시장에 대한 우려로 금리를 인하하기 때문이다. 파월 의장은 연준의 최대 고용 의무화를 계속해서 주장하면서 연준이 경제 지원을 위해 더 빠른 속도로 금리를 인하할 것이라는 점을 분명히 했다"고 그녀가 말했다.
노동 시장 상황이 악화되면 연준은 예정된 9월 18일 회의보다 더 빨리 완화 주기를 시작할 수도 있다고 크로스비는 말했다. 시장에서는 경기 호조 속에서 인플레이션 완화에 따른 금리 인하를 선호하고 있다.
<h2 class="wp-block-heading">이번 주 러셀 2000에서 가장 높은 성과를 기록한 상위 10개 회사 </h2>
<ol>
<li>모픽 홀딩 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>): 75.16% (헬스케어)</li>
<li>랜티우스 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>): 55.47% (헬스케어)</li>
<li>IGM 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>): 54.22% (헬스케어)</li>
<li>사운드하운드 AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>): 52.63% (정보기술)</li>
<li>메소드 일렉트로닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NASDAQ">MEI</a>): 47.96% (정보기술)</li>
<li>솔라리스 오일필드 인프라스트럭처 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOI#NYSE">SOI</a>): 46.87% (에너지)</li>
<li>펄스 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>): 45.98% (헬스케어)</li>
<li>아우스터 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>): 44.21% (정보기술)</li>
<li>EV고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>): 42.65% (소비자 자유롭게 선택 가능한 소비재)</li>
<li>선런 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>): 42.51% (산업재)</li>
</ol>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39750466/us-consumer-morale-dips-more-than-expected-in-july-sentiment-remains-stubbornly-subdued">미국 소비자 심리, 7월 예상보다 감소&#8230;전망은 &#8216;완고하게 억제된 상태&#8217;</a></li>
</ul>
사진: 셔터스톡
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Lantheus Holdings

뉴스

에 대한 최신 뉴스 Lantheus Holdings (NASDAQ:LNTH) 주식

일요일, 1월 19, 2025

월요일, 7월 15, 2024

금요일, 7월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌